Summary of the Ethopian country office of WHO on COVID-19 activities.
Mehrsprachige Aufklärung zu Symptomen und Prävention
Bebilderte Informationsbroschüre zum Coronavirus mit Symptomen, vorbeugenden Maßnahmen, Infektion und Quarantäne sowie Hände waschen.
Ideal für die Beratungssituation und zum Verteilen in Gemeinschaftsunterkünften. Aufgrund der dynamisch...en Lage wird die Broschüre schrittweise angepasst. Eine einzige Broschüre für alle Bundesländer gleichermaßen passend ist leider nicht möglich. Tippen Sie im Gespräch auf die Begriffe, die für Sie gerade am passendsten sind.
Sprachen: Deutsch, Albanisch, Arabisch, Bulgarisch, Englisch, Farsi, Französisch, Kurdisch, Polnisch, Rumänisch, Russisch, Serbisch, Tigrinya und Türkisch
more
Social and behavior change (SBC) professionals have often been tasked to find ways to influence knowledge, attitudes, and practices, about vaccines. Now that the COVID-19 vaccines are becoming available worldwide, renewed emphasis and urgency for SBC efforts arise.
To that end, WHO has offered thre...e factors that play a role in vaccine hesitancy, the first two of which can be addressed by SBC: Complacency: Low perceived risk of vaccine-preventable diseases, and vaccination not deemed necessary. Other life/health issues are a greater priority.
Confidence: Low levels of trust in vaccines, in the delivery system, and in health authorities
Convenience: Barriers related to geographic accessibility, availability, affordability, and acceptability of services
This resource page provide a selection of SBC research, tools, and examples that aid in understanding this issue, especially in light of the recent availability of COVID-19 vaccines and the urgency for immunization worldwide.
more
Health Situation
Health policies and systems
Cooperation for Health
WHO Country Cooperation Strategic Agenda (2008-2013)
17 February 2021
During the second joint meeting of African ministers responsible for health, ICT and transport on the rollout of the Africa Against COVID-19: Saving Lives, Economies and Livelihoods campaign, a call was made to African countries to work together towards harmonizing travel entry and... exit requirements, and to increase mutual recognition and cross-border information exchange for enhanced surveillance
more
Archives of Disease in Childhood 2021;106:238-240.
19 February 2021
The overall objective of this prospective meta-analyses (PMA) is to estimate the effect of anti-IL-6 therapy compared with usual care in hospitalized patients with suspected or confirmed COVID-19. The primary comparison is of the class effect of anti-IL-6 therapies. It will also es...timate the effects of specific anti-IL-6 therapies.
more
This infodemic management course applies evidence-based guidance to the COVID-19 pandemic. It covers key risk communication and community engagement (RCCE) principles and illustrates how they can be operationalized in the context of an extended outbreak that affects different populations with varyin...g risk levels. Illustrations from WHO headquarters, regions, and Ministries of Health provide concrete examples of messaging and other communication interventions developed during COVID-19.
more
his course is intended for decision-makers and programme managers who want to learn more about neglected tropical diseases (NTDs) in the context of the COVID-19 pandemic. Its 5 modules introduce NTDs, outline the impact of COVID-19 on NTD programmes and WHO’s response to mitigate its consequences,... and finally present WHO’s recommendations on maintenance of essential health services for NTDs as well as guidance on adaptation and safe resumption of community-based NTD activities during the pandemic.
more
Online Course. Infection prevention and control (IPC) is an essential component of healthcare quality and patient safety. In this module you will learn how and why healthcare-associated infections (HAIs) occur and how IPC reduces their risk and spread.
13 May 2021 The diagram supports health workers by outlining key steps and messages to communicate during a COVID-19 vaccination session.
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
at the World Trade Organization (WTO) Trade Related Aspects of Intellectual Property Rights (TRIPs) Council
23 Febur. 2021
1 March 2021
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
22 July 2022. This document provides the case definitions for public health surveillance of COVID-19 in humans caused by SARS-COV-2 infection.
This fact sheet provides basic information about Coronavirus Disease (COVID-19)